VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PRPO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
PRPOPrecipio, Inc.
$26.00$45M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksPRPOFinancials

Precipio, Inc. (PRPO) Financials

26Y historyFree accessUpdated daily

Revenue growth remains inconsistent, with 2025Q3 showing an 18.3% year-over-year increase, while gross margins continue to fluctuate significantly between 26.8% and 50.4% over the last ten quarters.

PRPO Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99
Sales/Revenue21.52M15.96M15.2M9.41M8.85M6.09M3.13M2.86M1.72M1.56M1.65M27.08M27.54M31.48M31.97M20.05M22.02M23.99M23.18M23.41M25.83M33.79M33.87M37.55M38.47M25.88M23.03M
Revenue Growth %23.63%5.05%61.46%6.36%45.26%94.82%9.18%66.22%10.66%-5.81%-93.9%-1.67%-12.5%-1.54%59.47%-8.97%-8.21%3.53%-1.02%-9.34%-23.56%-0.23%-9.82%-2.37%48.62%12.36%-
Cost of Goods Sold11.3M8.41M9.18M6.9M6.46M4.94M2.91M2.64M1.43M1.76M1.94M17.36M15.05M16.47M13.53M10.28M10.42M10.35M10.48M12.05M13.5M24.6M24.32M19.57M17.2M10.89M10.58M
COGS % of Revenue-52.65%60.4%73.33%72.97%81.12%93%92.14%83.05%113.17%117.36%64.11%54.63%52.32%42.33%51.3%47.31%43.12%45.23%51.45%52.26%72.79%71.8%52.11%44.71%42.08%45.91%
Gross Profit10.22M7.56M6.02M2.51M2.39M1.15M219K225K292K-205K-287K9.72M12.5M15.01M18.44M9.76M11.61M13.65M12.69M11.37M12.33M9.19M9.55M17.98M21.27M14.99M12.46M
Gross Margin %47.48%47.35%39.6%26.67%27.03%18.88%7%7.86%16.95%-13.17%-17.36%35.89%45.37%47.68%57.67%48.7%52.69%56.88%54.77%48.55%47.74%27.21%28.2%47.89%55.29%57.92%54.09%
Gross Profit Growth %-25.61%139.76%4.93%108%425.11%-2.67%-22.95%242.44%28.57%-102.95%-22.21%-16.75%-18.59%88.83%-15.86%-14.97%7.52%11.65%-7.8%34.13%-3.75%-46.89%-15.44%41.88%20.32%-
Operating Expenses12.3M11.78M13.64M15.31M12.01M10.3M11.21M9.45M6.49M7.61M8.91M27.04M28.25M24.51M21.37M13.24M13.5M13.26M14.5M14.5M14.84M34.68M31.4M36.4M31.01M24.47M19.34M
OpEx % of Revenue-73.76%89.74%162.63%135.66%169.01%358.59%330.03%376.55%489.02%538.9%99.85%102.58%77.87%66.84%66.03%61.3%55.27%62.56%61.93%57.46%102.65%92.72%96.93%80.61%94.53%83.97%
Selling, General & Admin2.19M11.78M13.64M13.61M10.71M10.3M9.62M9.45M6.49M6.19M7.05M24.15M25.04M22.02M19.15M10.93M10.32M10.79M11.47M12.14M12.22M17.5M17.32M24.2M21.64M14.91M11.53M
SG&A % of Revenue-73.76%89.74%144.57%120.97%169.01%307.74%330.03%376.55%397.69%426.8%89.16%90.92%69.96%59.9%54.53%46.86%44.99%49.47%51.84%47.31%51.79%51.15%64.44%56.25%57.6%50.06%
Research & Development2.3M2.3M2.7M1.7M1.3M2.2M2.79M1.1M500K1.42M1.85M2.9M3.21M2.49M2.22M2.31M3.18M2.46M3.03M2.36M2.2M6.68M9.3M12.2M9.37M7.65M6.3M
R&D % of Revenue-14.41%17.77%18.06%14.69%36.11%89.22%38.41%29.02%91.33%112.1%10.7%11.66%7.91%6.94%11.5%14.45%10.27%13.09%10.09%8.51%19.78%27.48%32.49%24.36%29.56%27.34%
Other Operating Expenses2M-2.3M-2.7M00-2.2M-1.2M-1.33M877K00000000000425K10.5M4.77M001.91M1.51M
Operating Income-2.08M-4.22M-7.62M-12.8M-9.61M-9.15M-10.99M-13.91M-15.51M-7.82M-9.2M-17.32M-15.76M-9.5M-2.97M-3.61M-1.9M-368K-3.32M-3.13M-2.51M-29.06M-22.59M-21.7M-9.74M-9.48M-6.88M
Operating Margin %-9.66%-26.41%-50.14%-135.96%-108.63%-150.13%-351.58%-485.75%-900.23%-502.18%-556.26%-63.96%-57.21%-30.19%-9.3%-18.02%-8.61%-1.53%-14.33%-13.37%-9.72%-86%-66.7%-57.78%-25.32%-36.61%-29.88%
Operating Income Growth %-44.67%40.45%-33.12%-5.11%16.81%20.97%10.31%-98.38%14.96%46.92%-9.92%-65.81%-219.78%17.72%-90.51%-415.22%88.92%-6.1%-24.69%91.36%-28.65%-4.11%-122.78%-2.76%-37.67%-
EBITDA-549K-2.7M-6.31M-11.28M-8.17M-8M-9.81M-12.65M-14.77M-7.71M-8.71M-15.07M-13.01M-7.23M-871K-2.9M-1.04M514K-2.37M-1.18M1.77M-25.05M-13.84M-17.7M-6.06M-7.57M-5.37M
EBITDA Margin %-2.55%-16.93%-41.53%-119.82%-92.32%-131.37%-313.82%-441.59%-857.11%-494.99%-526.68%-55.66%-47.24%-22.95%-2.72%-14.49%-4.73%2.14%-10.23%-5.05%6.86%-74.14%-40.85%-47.14%-15.75%-29.24%-23.31%
EBITDA Growth %83.39%57.18%44.03%-38.05%-2.07%18.44%22.41%14.36%-91.62%11.47%42.24%-15.86%-80.06%-729.62%70.01%-178.96%-302.53%121.67%-100.68%-166.7%107.07%-81.07%21.85%-192.19%19.95%-40.97%-
D&A (Non-Cash Add-back)1.53M1.51M1.31M1.52M1.44M1.14M1.18M1.26M743K112K489K2.25M2.75M2.28M2.1M708K855K882K950K1.95M4.28M4.01M8.75M3.99M3.68M1.91M1.51M
EBIT-1.17M-4.22M-7.62M-12.17M-8.5M-9.15M-9.4M-9.23M-6.2M-1.71M-9.14M-10.57M-15.4M-7.29M-2.93M-2.98M-1.9M388K-1.81M-3.13M-2.51M-7.22M-8.75M-18.41M-9.74M-9.48M-6.88M
Net Interest Income-86K-74K-18K-12K-20K-470K-473K-1.6M-2.32M-518K-724K-665K-642K-888K-958K-4K15K74K270K205K-1.98M-2.38M-155K564K2.39M226K0
Interest Income000000-00000000015K74K270K216K00160K626K2.45M2M0
Interest Expense86K74K18K12K20K470K473K1.6M2.32M518K724K665K642K888K958K4K00011K1.98M2.38M315K62K58K1.78M0
Other Income/Expense826K-74K1.77M619K1.1M-1.45M-2.32M-2.06M-5.18M-515K-1.22M3.9M-282K1.32M-6.76M628K18K86K243K198K-2.45M-5.26M-5.82M-2.98M2.36M996K-1.2M
Pretax Income-1.25M-4.29M-5.85M-12.18M-8.52M-10.6M-13.31M-15.97M-20.69M-8.27M-10.14M-13.42M-16.04M-8.18M-9.74M-2.98M-1.88M-282K-1.93M-2.93M-4.96M-34.47M-22.89M-21.26M-7.38M-8.48M-8.08M
Pretax Margin %-5.83%-26.87%-38.51%-129.39%-96.25%-173.97%-425.74%-557.72%-1201.04%-531.09%-613.31%-49.54%-58.24%-25.99%-30.46%-14.88%-8.53%-1.18%-8.33%-12.53%-19.2%-102%-67.6%-56.61%-19.18%-32.77%-35.08%
Income Tax000000-70K-279K0-203K23.76M524K-54K146K45K150K42K213K243K30K26K-94K65K105K24K180K1.75M
Effective Tax Rate %0%0%0%0%0%0%0.53%1.75%0%2.45%-234.36%-3.91%0.34%-1.78%-0.46%-5.03%-2.24%-75.53%-12.58%-1.02%-0.52%0.27%-0.28%-0.49%-0.33%-2.12%-21.6%
Net Income-1.25M-4.29M-5.85M-12.2M-8.55M-10.63M-13.24M-15.69M-20.69M-7.62M-32.95M-13.94M-15.99M-8.33M-9.78M-3.13M-1.92M-495K-2.11M-3.43M-14.99M-34.37M-22.96M-21.36M-7.4M-8.66M-9.83M
Net Margin %-5.83%-26.87%-38.51%-129.65%-96.62%-174.41%-423.5%-547.97%-1201.04%-489.15%-1993.59%-51.48%-58.04%-26.45%-30.6%-15.63%-8.72%-2.06%-9.09%-14.65%-58.05%-101.73%-67.79%-56.89%-19.24%-33.46%-42.66%
Net Income Growth %58.2%26.7%52.04%-42.73%19.53%19.77%15.62%24.16%-171.72%76.89%-136.36%12.79%-91.99%14.87%-212.13%-63.23%-287.88%76.51%38.59%77.12%56.38%-49.72%-7.46%-188.68%14.55%11.86%-
Net Income (Continuing)-1.25M-4.29M-5.85M-12.18M-8.52M-10.6M-13.24M-15.69M-20.69M-2.23M-9.86M-13.94M-15.99M-8.33M-9.78M-3.13M-1.92M-495K-2.17M-2.96M-4.98M-13.75M-9.51M-21.36M-7.4M-8.66M-9.83M
Discontinued Operations000000000000000000000000000
Minority Interest00065K40K27K000000000000000000000
EPS (Diluted)-0.77-2.93-4.51-10.73-8.10-14.84-46.51-217.80-1338.20-580.93-870.12-837.26-990.09-646.66-1070.24-343.68-210.78-54.34-231.31-376.70-2268.92-6399.55-5063.52-4892.37-1771.85-2812.93-4082.63
EPS Growth %59.04%35.03%57.97%-32.47%45.42%68.09%78.65%83.72%-130.35%33.24%-3.92%15.44%-53.11%39.58%-211.41%-63.05%-287.89%76.51%38.6%83.4%64.55%-26.39%-3.5%-176.12%37.01%31.1%-
EPS (Basic)--2.93-4.51-10.73-8.10-14.84-46.51-217.81-1338.20-580.93-870.12-837.26-990.09-646.66-1070.24-343.68-210.78-54.34-231.31-376.70-2268.92-6399.55-5063.52-4892.37-1771.85-2812.93-4082.63
Diluted Shares Outstanding1.64M1.47M1.3M1.14M1.05M823.85K284.76K72.06K15.46K481.37K006434574564554554554553302694.53K4.37K4.18K3.08K2.41K
Basic Shares Outstanding1.64M1.47M1.3M1.14M1.05M823.85K284.76K72.06K15.46K481.37K006434574564554554554553302694.53K4.37K4.18K3.08K2.41K
Dividend Payout Ratio---------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and dilution risk

Revenue Growth Lacks Consistent Momentum

According to the provided quarterly income statements, Precipio's revenue growth has fluctuated significantly, with the most recent 2025Q3 period showing an 18.3% year-over-year increase, yet the lack of a sustained upward trajectory suggests challenges in scaling the HemeScreen platform adoption across the broader diagnostic market.

The volatility in quarterly revenue growth indicates that the company's transition toward a product-heavy model remains inconsistent. Investors should monitor whether the current growth rate can stabilize, as the firm relies on recurring reagent sales to offset the inherent lumpiness of its diagnostic service business.

Gross Margin Volatility Hinders Profitability

As reported in financial statements, Precipio's gross margin has fluctuated between 26.8% and 50.4% over the last ten quarters, reflecting the inherent difficulty in maintaining consistent pricing power while managing the specialized costs associated with its proprietary diagnostic reagent kits and laboratory service infrastructure.

The inability to maintain a stable gross margin suggests that the company's unit economics are highly sensitive to shifts in product mix and potential reimbursement pressures. This variability complicates the path to sustainable profitability, as the firm must achieve higher scale to absorb its fixed laboratory overhead.

Operating Leverage Remains Elusive Today

Based on Precipio's reported figures, the company has struggled to achieve meaningful operating leverage, as evidenced by persistent operating losses that frequently track closely with gross profit levels, indicating that corporate overhead and R&D expenses continue to outpace the firm's ability to generate scalable diagnostic revenue.

The company's operating margin remains deeply negative, suggesting that the current cost structure is not yet optimized for the existing revenue base. Without a significant inflection in top-line growth, the firm may continue to face difficulty in achieving the economies of scale necessary to reach break-even.

Earnings Quality Obscured by Volatility

Analysis of the income statement reveals that reported net income is frequently impacted by non-operating items and significant stock-based compensation, which, as noted in recent filings, reached $449,000 in 2025Q2, potentially masking the underlying cash burn and the true operational performance of the diagnostic business.

The reliance on equity-based compensation and the presence of irregular net income swings suggest that investors should focus on cash-based metrics rather than headline EPS. The frequent adjustments and non-cash charges warrant further investigation into the sustainability of the company's current operating model.

Sustainability of Current Business Model

Short-sellers would likely focus on the company's precarious cash position of $1.389 million, which, when viewed against the backdrop of consistent operating losses, suggests that the current business model may be unsustainable without further dilutive financing or a rapid, unproven pivot to high-margin product sales.

The persistent negative operating margins and limited liquidity create a high-risk profile that may necessitate additional capital raises. Investors should remain cautious, as the company's ability to fund its operations remains contingent on market conditions that are currently unfavorable for micro-cap diagnostic firms.

PRPO — Frequently Asked Questions

Quick answers to the most common questions about buying PRPO stock.

What was Precipio, Inc.'s (PRPO) revenue in 2024?

For fiscal year 2024, Precipio, Inc. (PRPO) reported total revenue of $16.0M. This represents a 30.7% decline compared to $23.0M in 1999.

Is Precipio, Inc. (PRPO) profitable?

Precipio, Inc. (PRPO) reported a net loss of $4.3M for the fiscal year ending 2024.

What is Precipio, Inc.'s operating profit margin?

Precipio, Inc. (PRPO) reported an operating income of $-4.2M, resulting in an operating profit margin of -26.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Precipio, Inc.'s gross profit and gross margin?

Precipio, Inc. (PRPO) generated $7.6M in gross profit for the year, representing a gross profit margin of 47.3%. This demonstrates the company's core pricing power and production efficiency.